CytoImmune Therapeutics Expands Phase 1 Trial of CYTO-102

Phase 1 study of CYTO-102 with atezolizumab (Tecentriq®) at Chan Soon-Shiong Institute for Medicine pioneers new avenues in cancer therapy TOA BAJA, Puerto Rico, Dec. 14, 2023 /PRNewswire-PRWeb/ -- CytoImmune Therapeutics announces today a significant extension of its ongoing Phase 1...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news